Exelixis (NASDAQ:EXEL) is scheduled to release its earnings data after the market closes on Monday, February 26th. Analysts expect Exelixis to post earnings of $0.12 per share for the quarter.
Exelixis (EXEL) opened at $29.51 on Friday. Exelixis has a 1-year low of $18.03 and a 1-year high of $32.50. The stock has a market cap of $8,730.00, a PE ratio of 60.22, a P/E/G ratio of 0.81 and a beta of 1.84.
In other Exelixis news, Director Alan M. Garber sold 15,000 shares of the business’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $30.30, for a total value of $454,500.00. Following the completion of the transaction, the director now directly owns 64,829 shares of the company’s stock, valued at $1,964,318.70. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 5.10% of the company’s stock.
Several brokerages recently issued reports on EXEL. Oppenheimer reissued a “hold” rating on shares of Exelixis in a report on Wednesday, January 17th. BidaskClub downgraded shares of Exelixis from a “buy” rating to a “hold” rating in a report on Friday, January 19th. Cann reissued a “hold” rating on shares of Exelixis in a report on Thursday, January 4th. SunTrust Banks reissued a “buy” rating and set a $38.00 price target on shares of Exelixis in a report on Thursday, December 21st. Finally, William Blair reissued an “outperform” rating on shares of Exelixis in a report on Monday, February 12th. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $32.13.
WARNING: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/24/exelixis-exel-to-release-earnings-on-monday.html.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.